Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line

Tumori

Volumn 97, Issue 2, 2011, Pages 196-202

  Choi, June ^a   Lee, Min Koo ^b   Oh, Kyoung Ho ^a   Kim, Yeon Soo ^a   Choi, Han Young ^a   Baek, Seung Kuk ^a   Jung, Kwang Yoon ^a   Woo, Jeong Soo ^a   Lee, Seung Hoon ^a   Kwon, Soon Young ^a  

^a Korea University Ansan Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

HMGB 1; Migration; Nifedipine; RAGE; SCC7 cell line; Squamous cell carcinoma

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; NIFEDIPINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

EID: 79957663123     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700211     Document Type: Article

References (20)

1. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A: The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch, 450: 287-295, 2007. (Pubitemid 46376559)
2. Bhawal UK, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T: Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology, 69: 246-255, 2005. (Pubitemid 41433583)
3. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H: Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol, 122: 461-467, 2004. (Pubitemid 38281070)
4. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate, 64: 92-100, 2005. (Pubitemid 40734743)
5. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol, 196: 163-170, 2002. (Pubitemid 34110897)
6. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol, 5: 331-342, 2005. . (Pubitemid 40516158)
7. Riuzzi F, Sorci G, Donato R: The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem, 281: 8242-8253, 2006. (Pubitemid 43847445)
8. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405: 354-360, 2000. (Pubitemid 30337069)
9. Matsui T, Yamagishi S, Nakamura K, Inoue H, Takeuchi M: Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J Int Med Res, 35: 107-112, 2007. (Pubitemid 46477534)
10. Yamagishi S, Nakamura K, Takeuchi M: Potential therapeutic implication of nifedipine, a dihydropyridine-based calciumantagonist, in advanced glycation end product (AGE)- related disorders.Med Hypotheses, 65: 392-394, 2005. (Pubitemid 40744774)
11. Yamagishi S, Takeuchi M: Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res, 30: 169-175, 2004. (Pubitemid 39487685)
12. Jiang W, Pisetsky DS: The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. J Immunol, 177: 3337-3343, 2006. (Pubitemid 44277853)
13. Schmidt AM, Stern DM: Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci, 6: D1151-1160, 2001.
14. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med, 83: 876-886, 2005. (Pubitemid 41598688)
15. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J, 16: 1928-1930, 2002.
16. Lin L: RAGE on the Toll Road? Cell Mol Immunol, 3: 351-358, 2006.
17. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y: Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res, 888: 256-262, 2001. (Pubitemid 32058790)
18. Hoffman S, Gopalakrishna R, Gundimeda U, Murata T, Spee C, Ryan SJ: Verapamil inhibits proliferation, migration and protein kinase C activity in human retinal pigment epithelial cells. Exp Eye Res, 67: 45-52, 1998. (Pubitemid 28364813)
19. Farias EF, Aguirre Ghiso JA, Ladeda V, Bal de Kier Joffe E:Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. Int J Cancer, 78: 727-734, 1998. (Pubitemid 28530396)
20. Wu Y, Palad AJ, Wasilenko WJ, Blackmore PF, Pincus WA, Schechter GL: Inhibition of head andneck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Clin Cancer Res, 3: 1915-1921, 1997.